HIV Disease Pathogenesis
|
|
- Delilah Bradford
- 6 years ago
- Views:
Transcription
1 Slide Presentation HIV Disease Pathogenesis Bethesda, MD What Do We Mean by Pathogenesis Today? 1 Survival from Age 25 Years (N = 3,990) Probability of Survival Age Increased life expectancy in the era of HAART Late HAART ( ) Early HAART ( ) Pre-HAART ( ) Lohse N. Ann Intern Med. 2007; ART-CC, Lancet, 2008; Lewden, JAIDS, 2007; van Sighem, AIDS, 2010 What Do We Mean by Pathogenesis Today? 1 Survival from Age 25 Years (N = 3,990) Probability of Survival Age Population controls Late HAART ( ) Early HAART ( ) Pre-HAART ( ) Life span of ART-treated patients is 10 years less than that of uninfected people, esp. if therapy is started late. Lohse N. Ann Intern Med. 2007; ART-CC, Lancet, 2008; Lewden, JAIDS, 2007; van Sighem, AIDS, 2010
2 What Do We Mean by Pathogenesis Today? Cardiovascular disease 1-3 Cancer (non-aids) 4 Bone fractures/osteopenia 5,6 Liver failure 7 Kidney failure 8 Cognitive decline 9 Frailty 10 ART-CC. CID : Klein D. JAIDS : Hsue P. Circulation : Grinspoon SK. Circulation : Patel P. Ann Int Med, 2008;148: Triant V. JCEM : Arnsten JH. AIDS : Odden MC. Arch Int Med : Choi A. AIDS : McCutchan JA. AIDS : Desquilbet L. JGBSMSci : Almost two-thirds of deaths in the late ART era are non-aids associated. Non-AIDS events are greater in treated HIV disease than in uninfected people even after adjusting for age, ART, and traditional risk factors. What We Talk About When We Talk About Immune Activation Immune activation occurs early in infection. Virus load Cytokine A.R. Stacey et al JV 2009 Normal innate response to viral infection in the acute phase of the infection What We Talk About When We Talk About Immune Activation As virus load decreases, immune activation persists. Innate Cells: activation of macrophages and dendritic cells Cytokines, chemokines: IFNa, TNF, IL-1, IL-6, IL-8, IL-15, IL-10 Acute-phase proteins: serum amyloid A, C-reactive protein Coagulation: D-dimers, tissue factor Fibrosis: matrix metalloproteinase activation, collagen deposition Microbial sensors: lipopolysaccharide-binding protein, soluble CD14 Adaptive T cells: increased turnover, exhaustion, low thymic output, virus reservoir B cells: increased turnover, exhaustion, hypergammaglobulinemia Frequency of activated T cells is a strong predictor of disease progression.
3 Causes of Chronic Immune Activation HIV-induced activation of innate immune system (Bhardwaj) When virus load decreases after acute phase, immune activation remains elevated. Virus load alone is a poor predictor of disease progression (Rodriguez JAMA 2006). Immune activation predicts disease progression independent of viral load (Giorgi, Deeks etc). Elite controllers who progress have increased activated CD38+ T cells (Hunt JID 2008). When virus load is suppressed with ART, activation persists and predicts progression. Increased antigen load, bacterial overgrowth, herpes viruses (Deeks) Defective tryptophan metabolism (McCune, Hunt) Immunologic and structural damage to gut, increased mucosal permeability, translocation of inflammatory microbial products into systemic circulation Consequences of HIV Infection in GI Tract Mucus Loss of tight junctions Microbial products Enterocyte apoptosis CD4 T cell loss Healthy Gut Tight epithelial junctions, mucus Antimicrobial peptides, Abs, cells Majority of CD4 T cells in body Cross talk between microbes and epithelial and immune cells HIV-Infected Gut Massive loss of CD4 T cells Enteropathy 2-10x increased permeability Translocation of microbial products Systemic immune activation gut CD4 depletion enteropathy HIV Tcm Tcm immune activation
4 immune deficiency gut CD4 depletion enteropathy HIV Tcm immune activation CMV??? non-aids morbidity and mortality low thymic output LT fibrosis T/B cell dysfunction inflammation tissue damage coagulopathy Tcm Tcm immune deficiency gut CD4 depletion enteropathy HIV ART immune activation CMV??? non-aids morbidity and mortality low thymic output LT fibrosis T/B cell dysfunction inflammation tissue damage coagulopathy Markers of Inflammation and GI Dysfunction Predict Mortality Microbial translocation Inflammation Coagulation Hunt, CROI 2012 T cells %CD38 + DR + %CD57 + DR + Odds of Mortality (4 th vs 1 st Quartile) (Independent of CD4 count and virus load) Markers of inflammation and gut barrier dysfunction predict mortality independently of CD4 count and virus load.
5 When Immune Activation Turns to the Dark Side Good Antiviral innate immune response Restoration of memory CD4 T cells Bad Target cell generation HIV replication Thymic dysfunction T- and B-cell exhaustion Macrophage/DC activation Cytokine/chemokine secretion Lymph node fibrosis Generalized tissue fibrosis Coagulation cascade activation Immune Activation and HIV Persistence Does inflammation contribute to HIV persistence? Does HIV replication contribute to persistent inflammation? Can novel therapies reduce reservoir size? Anti-inflammatory drugs Enhanced HIV-specific immunity It is difficult to establish cause and effect. Immune Activation and HIV Persistence Slide 16 of 38 % activated memory CD4 T cells LAT24F_L_An_3p_4p_38pDRp Correlation r=0.689, p= Total HIV DNA (copies/million resting memory CD4 cells); digital PCR Frequency of HIV DNA-containing resting memory CD4 T cells correlates with frequency of activated CD4 T cells.
6 Immune Activation and HIV Persistence Katlama CROI 2013 IL-7 causes CD4 T-cell proliferation without virus production but with increased HIV-infected CD4 T-cell reservoir. Raltegravir Intensification No association between plasma measures of viral persistence and T-cell activation in blood. Raltegravir Intensification %CD38 + memory CD8 T cells P < Nat Med 2010 P = P = P = P < Intensified Control Llibre, Buzón, Massanella et al. Antiv Ther 2011 Raltegravir intensification reduces immune activation and virus replication significantly more than conventional therapy.
7 Raltegravir Intensification Raltegravir intensification in nine subjects resulted in decrease in infectious virus and CD8 T-cell activation. Raltegravir Intensification JID 2013 Rapid increase in the level of 2-LTR circles and decrease in D-dimers in some subjects. Viral replication persists in some individuals even after long-term ART and is associated with inflammatory biomarkers. Virus and Immune Activation in Tissues Raltegravir intensification reduces immune activation and HIV RNA levels in gut tissue sites.
8 How Big Is the Reservoir? It was thought that <1% of HIV sequences in cells are replication competent. Cell % of HIV sequences in cells have identifiable defects. 12% have intact genomes and may be replication competent. Size of the latent reservoir, and hence the barrier to cure, may be up to 60-fold greater than previously estimated. Ongoing HIV Replication During ART? Although complete inhibition of viral replication is unlikely to be curative, all cure strategies are based on first having achieved complete suppression. Evidence against ongoing HIV replication on ART. Increasing evidence in favor of ongoing replication. Evidence it is associated with immune activation. The source of the sample is key (blood vs tissues). The assay used to measure virus is critical. Virus Persistence on cart: A5276 Virus persistence by single copy assay (SCA) of plasma virus SCA on patients at ~4, 7, and 11 years on suppressive ART (n=64) Yr 4: N (%) Yr 7: RNA > 1 c/ml Yr 10: RNA > 1 c/ml +/+ (persistent) 17 (27) 65% 56% +/- (intermittent) 25 (39) 32% 36% -/- (negative) 22 (34) 14% 9% Persistent viremia at year 4 often still positive at years 7 and 10 Absence of viremia at year 4 often still negative at years 7 and 10 No change in pvl over time if persistent viremia (median ~ 1.4 c/ml) Riddler SA, et al. CROI 2014, Abstract #420
9 Ongoing HIV Replication During ART? Day 0 Month 1 Month 3 Month 6 100% PNAS 2014 Median Percent Difference of LN from PBMC Concentrations #1 #2 #3 #4 n/a Median % Difference 50% 0% -50% -100% LN Ileum Rectum TFV-DP FTC-TP ATV DRV EFV Persistent virus replication in lymph nodes during ART is associated with lower levels of ARVs in tissues. Immune Activation and HIV Persistence A. What mechanisms associate immune activation with HIV persistence? B. How may they direct therapeutic interventions? immune deficiency gut Tcm Tcm ART immune activation CMV??? low thymic output LT fibrosis T/B cell dysfunction non-aids morbidity and mortality inflammation tissue damage coagulopathy
10 target cell generation infected cell proliferation virus transcription virus production new infection events immune activation low thymic output lymphoid fibrosis poor CD4 T-cell renewal T/B-cell dysfunction mucosal damage Therapeutic Interventions in Development Chemokine receptor inhibitors: maraviroc, TB-652 Anti-infective therapy: CMV, EBV, HSV, HCV/HBV Microbial translocation: sevelamer, colostrum, rifaximin Enhance T-cell renewal: growth hormone, IL-7 Antifibrotic drugs: pirfenidone, ACEi, ARBs, KGF Anti-aging: caloric restriction, sirtuin activators, vit. D, omega-3 fatty acids, rapamycin, diet, exercise (not recommended by me) Anti-inflammatory drugs: chloroquine, hydroxychloroquine minocycline NSAIDs (COX-2i, aspirin) statins methotrexate anakinra (IL-1Ra) thalidomide, lenalidomide, pentoxyfylline (weak TNF inhibitors) biologics (TNFi, IL-6i, anti-ifna, anti-pd1, anti-pdl1, JAKi, IDOi, Casp-1i) Anticoagulants: warfarin, dabigatran, aspirin, clopidogrel Combination therapy may be necessary. Therapeutic Interventions in Studies LPS fold increase Sevelamer: Pandrea, CROI 2013 Probiotics: Klatt et al. JCI 2013 DR + CD38 + CD4 T cells %CD4 T cells in colon ARV + Probiotic ARV Bovine colostrum: Asmuth, Douek et al. AIDS 2013 scd14 µg/ml P=0.740 P=0.008 D0 D28 W12 % mucosal CD4 + T cells P < P= P= Baseline W12 HIV- IL-7: Sereti et al. PLoS Path 2014
11 In the Context of the Cure Multiple mechanisms account for HIV persistence, all of which are being addressed therapeutically. The unifying theme is to reduce HIV reservoir size. Reduce inflammation. Increase immune function. Vaccines may enhance host-clearance mechanisms. Early ART and ART intensification. Drugs with biologic activity against latent virus exist. Gene therapy to reduce reservoir size. Stem cell transplants can reduce reservoir size. Combination therapy may be necessary. Berlin and Boston Patients HSCT/Patient Factor Berlin Patient Boston Patient A Boston Patient B Cancer AML Hodgkin s lymphoma Hodgkin s lymphoma Mode of acquisition Sexual (adult) Perinatal Sexual (adult) Favorable HLA alleles? No No No Type of HSCT HLA identical ( 10 of 10 match ) HLA C-mismatched, unrelated donor Matched related donor CCR5 genetics of graft 32 Homozygous 32 Heterozygous 32 Heterozygous HSCT conditioning Myeloablative Reduced intensity Reduced intensity GVHD Acute and chronic, no active disease Immunosuppression Cyclosporine A, methylprednisolone, mycophenolate mofetil Acute and chronic, no active disease Tacrolimus ART regimen pre-ati TDV/FTC/EFV TDF/FTC/EFV TDF/FTC/RAL Length of ART post-hsct None 4.5 years 2.8 years Acute and chronic, no active disease None (during ATI) Pre-HSCT HIV-1 DNA Unknown 144 copies/10 6 PBMC 96 copies/10 6 PBMC Time to recrudescence Cured 12 weeks 32 weeks Adapted from Heinrich CROI 2014 Patient A: Where Did the Virus Come From? Consensus B HIV-1 DNA pre-hsct Heinrich CROI 2014 Plasma RNA 5 days after rebound A single virus accounts for recrudescence
12 The Importance of Target Cell Availability HSCT/Patient Factor Berlin Patient Boston Patient A Boston Patient B Cancer AML Hodgkin s lymphoma Hodgkin s lymphoma Mode of acquisition Sexual (adult) Perinatal Sexual (adult) Favorable HLA alleles? No No No Type of HSCT HLA identical ( 10 of 10 HLA C-mismatched, Matched related donor match ) unrelated donor CCR5 genetics of graft 32 Homozygous 32 Heterozygous 32 Heterozygous HSCT conditioning Myeloablative Reduced intensity Reduced intensity GVHD Acute and chronic, no active disease Immunosuppression Cyclosporine A, methylprednisolone, mycophenolate mofetil Acute and chronic, no active disease Tacrolimus ART regimen pre-ati TDV/FTC/EFV TDF/FTC/EFV TDF/FTC/RAL Length of ART post-hsct None 4.5 years 2.8 years Acute and chronic, no active disease None (during ATI) Pre-HSCT HIV-1 DNA Unknown 144 copies/10 6 PBMC 96 copies/10 6 PBMC Time to recrudescence Cured 12 weeks 32 weeks Adapted from Heinrich CROI 2014 Thanks for the Memories Netanya Sander Jason Brenchley Tim Schacker Steve Deeks Peter Hunt Jake Estes Sarah Palmer Joe Wong Rick Hecht Nicolas Chomont Rafick Sekaly Michael Lederman and the BBC and loads of other wonderful people VRC NIAID Office of AIDS Research GATES
Perspective Immune Activation, HIV Persistence, and the Cure
AS USA Perspective mmune Activation, HV Persistence, and the Cure HV infection is characterized by persistent immune activation, even in the context of suppressive antiretroviral therapy. This persistent
More informationCOMPETING INTEREST OF FINANCIAL VALUE
BHIVA AUTUMN CONFERENCE 2013 Including CHIVA Parallel Sessions Dr Daniel Douek Vaccine Research Center, National Institute of Health, Bethesda, Maryland, USA COMPETING INTEREST OF FINANCIAL VALUE > 1,000:
More informationpersistence during therapy Professor of Medicine University of California, San Francisco
The clinical implications of HIV persistence during therapy Steven G. Deeks Professor of Medicine University of California, San Francisco T cell activation declines during long-term HAART, but remains
More informationWith over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the
Towards an HIV Cure Steven G. Deeks, MD Professor of Medicine in Residence HIV/AIDS Division University of California, San Francisco (UCSF) WorldMedSchool; July 22, 2013 1 With over 20 drugs and several
More informationHIV Pathogenesis and Natural History. Peter W. Hunt, MD Associate Professor of Medicine University of California San Francisco
HIV Pathogenesis and Natural History Peter W. Hunt, MD Associate Professor of Medicine University of California San Francisco Learning Objectives Describe key features of HIV pathogenesis and natural history
More informationImmune Activation: Impact on Outcomes Peter W. Hunt, MD. Associate Professor of Medicine University of California San Francisco
Immune Activation: Impact on Outcomes Peter W. Hunt, MD Associate Professor of Medicine University of California San Francisco 10y Decreased Life Expectancy in Older HIV+ Adults in Modern ART Era ~9y shorter
More informationImmunologic Failure and Chronic Inflammation. Steven G. Deeks Professor of Medicine University of California, San Francisco
Immunologic Failure and Chronic Inflammation Steven G. Deeks Professor of Medicine University of California, San Francisco Plasma HIV RNA (log) 6 5 4 3 2 52 year old HIV+/HCV+ man presents with symptomatic
More informationNew Insights in Pathogenesis Inflammation and Immune Activation
Activity Code TM809 New Insights in Pathogenesis Inflammation and Immune Activation Turner Overton, M.D. Associate Professor of Medicine University of Alabama at Birmingham Learning Objectives Upon completion
More informationTowards an HIV Cure. Steven G. Deeks Professor of Medicine University of California, San Francisco
Towards an HIV Cure Steven G. Deeks Professor of Medicine University of California, San Francisco Why are we now talking about a cure? Emerging recognition that HAART does not fully restore health and/or
More informationOutline. Epidemiology of Pediatric HIV 10/3/2012. I have no financial relationships with any commercial entity to disclose
Nutritional, Metabolic, and Gastrointestinal Complications in Pediatric HIV Infection Tracie L. Miller, MD Department of Pediatrics University of Miami, Miller School of Medicine I have no financial relationships
More informationThe Immune Aspects of HIV Malignancy, Aging, and End- Organ Disease
The Immune Aspects of HIV Malignancy, Aging, and End- Organ Disease Peter W. Hunt, MD Assistant Professor of Medicine UCSF HIV/AIDS Division Disclosures Research Grant Support Roche, Pfizer, Salix Consulting
More informationProfessor Jonathan Weber
HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust Multidisciplinary Event to mark World AIDS Day 2011 British HIV Association (BHIVA) 2011 HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust
More informationCoagulation and Morbidity in Treated HIV Infection. Michael M. Lederman, MD Scott R. Inkley Professor of Medicine Case Western Reserve University
Coagulation and Morbidity in Treated HIV Infection Michael M. Lederman, MD Scott R. Inkley Professor of Medicine Case Western Reserve University Although survival has improved, predicted life expectancy
More informationcure research HIV & AIDS
Glossary of terms HIV & AIDS cure research Antiretroviral Therapy (ART) ART involves the use of several (usually a cocktail of three or more) antiretroviral drugs to halt HIV replication. ART drugs may
More informationHIV e infarto miocardico: un problema dimenticato?
HIV e infarto miocardico: un problema dimenticato? Leonardo Calza Clinica di Malattie Infettive, Policlinico S.Orsola-Malpighi, Università degli Studi di Bologna CVD and HIV disease. The current issues
More informationHIV Pathogenesis Virus or Host? Turner Overton, M.D. Associate Professor of Medicine University of Alabama at Birmingham
HIV Pathogenesis Virus or Host? Turner Overton, M.D. Associate Professor of Medicine University of Alabama at Birmingham Goals At the conclusion of this presentation, learners should be better able to:
More informationImmune Regulation and T Cell Activation in HIV Disease
Immune Regulation and T Cell Activation in HIV Disease Peter W. Hunt, MD Assistant Professor UCSF HIV/AIDS Division To appraise: Learning Objectives Role of immune activation in HIV pathogenesis Persistence
More informationImpact of Persistent Immune Activation in Treated HIV Infection
Impact of Persistent Immune Activation in Treated HIV Infection Peter W. Hunt, MD Associate Professor of Medicine in Residence UCSF/SFGH HIV/AIDS Division Life Expectancy * May Start to Approach General
More informationCROI 2016 Review: Immunology and Vaccines
Frontier AIDS Education and Training Center CROI 2016 Review: Immunology and Vaccines Meena Ramchandani MD MPH Acting Instructor, University of Washington March 2016 This presentation is intended for educational
More informationHIV AND INFLAMMATION: A NEW THREAT
HIV AND INFLAMMATION: A NEW THREAT KAP ANNUAL SCIENTIFIC CONFERENC MAY 2013 DR JOSEPH ALUOCH FRCP,EBS Basic Components of the Immune System Immunology: cells and tissues involved in recognizing and attacking
More informationInclusion/Exclusion Criteria
The Immunomodulatory Effects of Intensification among ART-suppressed Patients with Incomplete CD4 Recovery Peter W. Hunt, Nancy Shulman, Tim Hayes, Viktor Dahl, Ma Somsouk, Nick Funderburg, Alan L. Landay,
More informationRecent Insights into HIV Pathogenesis and Treatment: Towards a Cure
Recent Insights into HIV Pathogenesis and Treatment: Towards a Cure Deborah Persaud, M.D. Associate Professor Department of Pediatrics Division of Infectious Diseases Johns Hopkins University School of
More informationModule R: Recording the HIV Reservoir
Module R: Recording the HIV Reservoir Satish K. Pillai, Ph.D. MODULE LEADER Satish Pillai amfar Institute for HIV Cure Research Module R Team Michael Busch Timothy Henrich Sheila Keating Sulggi Lee Henry
More informationCan HIV be cured? (how about long term Drug free remission?)
Can HIV be cured? (how about long term Drug free remission?) Shirin Heidari International AIDS Society EC Think Tank meeting 27-28 October 2010 Luxemburg HAART can control HIV, cannot eradicate it Life
More informationThe HIV Cure Agenda. CHIVA Oct Nigel Klein. Institute of Child Health and Great Ormond Street Hospital, London, UK
The HIV Cure Agenda CHIVA Oct 2016 Nigel Klein Institute of Child Health and Great Ormond Street Hospital, London, UK 2 How frequently is HIV cured? The Berlin patient Restriction of HIV entry CD4 is
More informationWorking Group#1: Trial Endpoints, Biomarkers & Definitions
Working Group#1: Trial Endpoints, Biomarkers & Definitions Forum HIV Cure Project: Focus on The Regulatory Pathway June 17, 2014 www.hivforum.org Comments from co-chairs john mellors and mike miller www.hivforum.org
More informationHIV Antibody Characterization for Reservoir and Eradication Studies. Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks
HIV Antibody Characterization for Reservoir and Eradication Studies Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks Blood Systems Research Institute University of California San Francisco, CA
More informationImmunology. Anas Abu-Humaidan M.D. Ph.D. Transplant immunology+ Secondary immune deficiency
Immunology Anas Abu-Humaidan M.D. Ph.D. Transplant immunology+ Secondary immune deficiency Transplant Immunology Transplantation is the process of moving cells, tissues or organs from one site to another
More informationHow HIV Causes Disease Prof. Bruce D. Walker
How HIV Causes Disease Howard Hughes Medical Institute Massachusetts General Hospital Harvard Medical School 1 The global AIDS crisis 60 million infections 20 million deaths 2 3 The screen versions of
More information5/11/2017. HIV Cure Research Questions and a Few Answers
HIV Cure Research Questions and a Few Answers Steven G. Deeks, MD Professor of Medicine University of California San Francisco San Francisco, California FORMATTED: 04/13/17 Financial Relationships With
More informationHIV Reservoirs in Developing Countries: Implication for HIV CURE Strategies
HIV Reservoirs in Developing Countries: Implication for HIV CURE Strategies 10 th INTEREST CONFERENCE 2016, 3-6 TH May 2016, Yaoundé, Cameroon Cissy Kityo 1 ; Thomas Schacker 2 ; Francis Ssali 1 ; Jeffrey
More informationMedical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University
Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve
More informationSustained HIV- 1 remission following homozygous CCR5 delta- 32 allogeneic haemopoetic stem cell transplantion
Sustained HIV- 1 remission following homozygous CCR5 delta- 32 allogeneic haemopoetic stem cell transplantion R Gupta 1, A Abdulijawad 2, L McCoy 2, D Peppa 3, M Salgado 4, J Martinez- Picado 4, A Wensing
More informationHIV and transplant: obstacles and opportunities
HIV and transplant: obstacles and opportunities Christine Durand, M.D. 18 de abril de 2013, XI Conferência Brasil Johns Hopkins University em HIV/AIDS Outline Part 1: Solid organ transplant (SOT) Part
More informationAlexander O. Pasternak, Mirte Scherpenisse, Ben Berkhout
Cell-associated HIV-1 unspliced to multiply spliced RNA ratio at 12 weeks ART correlates with markers of immune activation and apoptosis and predicts the CD4 + T-cell count at 96 weeks ART Alexander O.
More informationDr Jintanat Ananworanich
BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Dr Jintanat Ananworanich US Military HIV Research Program in Bethesda Maryland, USA 9-10 October 2014, Queen Elizabeth II Conference Centre,
More informationImmunodeficiency. (2 of 2)
Immunodeficiency (2 of 2) Acquired (secondary) immunodeficiencies More common Many causes such as therapy, cancer, sarcoidosis, malnutrition, infection & renal disease The most common of which is therapy-related
More informationBeyond HAART: Outline. HIV-1 Time Line. Outline. Approaches to HIV Eradication 8/15/2013
8/5/203 Beyond HAART: Approaches to HIV Eradication I have no financial conflicts of interest to disclose 8 August 203 Adam Spivak MD Visiting Instructor, Division of Infectious Diseases University of
More informationThe Eras of the HIV Epidemic
The Eras of the HIV Epidemic 1930-1980 1981-1986 1987-1995 1996-2005 2nd Gen. HAART 2006-2011 2006: Disproportionate distribution of HIV 2006: Gates and Clinton at International AIDS conference announce
More informationHIV-Associated Inflammation: Do the drugs matter? Jun 15, 2018 Darrell H. S. Tan MD FRCPC PhD
HIV-Associated Inflammation: Do the drugs matter? Jun 15, 2018 Darrell H. S. Tan MD FRCPC PhD Faculty/Presenter Disclosure Faculty: Darrell H. S. Tan Relationships with financial sponsors / potential for
More informationHIV Basics: Pathogenesis
HIV Basics: Pathogenesis Michael Saag, MD, FIDSA University of Alabama, Birmingham Director, Center for AIDS Research ACTHIV 2011: A State-of-the-Science Conference for Frontline Health Professionals Learning
More informationHow to best manage HIV patient?
How to best manage HIV patient? 1 2 Treatment Treatment Failure success HIV therapy = a long life therapy Why do we want to change a suppressive ART? Side effect Comorbidities Reduce drug burden How to
More informationSystem Biology analysis of innate and adaptive immune responses during HIV infection
System Biology analysis of innate and adaptive immune responses during HIV infection Model of T cell memory persistence and exhaustion Naive Ag+APC Effector TEM (Pfp, Gr.B, FasL, TNF) Ag stim. IL-2, IL-7,
More informationHIV remission: viral suppression in the absence of ART. Sarah Fidler Brian Gazzard Lecture BHIVA 2016
HIV remission: viral suppression in the absence of ART Sarah Fidler Brian Gazzard Lecture BHIVA 2016 Disclosures: My institution receives funding for research from MSD, GSK, ViiV, Gilead Summary of talk
More informationHIV 101: Fundamentals of HIV Infection
HIV 101: Fundamentals of HIV Infection David H. Spach, MD Professor of Medicine University of Washington Seattle, Washington Learning Objectives After attending this presentation, learners will be able
More informationStandardization of Immune Biomarkers: Lessons From the HIV Field
Standardization of Immune Biomarkers: Lessons From the HIV Field Alan Landay, PhD Rush University Medical Center Thomas Denny, MSc Duke University Medical Center and Viral Load Standardization Immunology
More informationViral Reservoirs and anti-latency interventions in nonhuman primate models of SIV/SHIV infection
Viral Reservoirs and anti-latency interventions in nonhuman primate models of SIV/SHIV infection Koen Van Rompay California National Primate Research Center University of California Davis Outline Introduction
More informationMHRP. Outline. Is HIV cure possible? HIV persistence. Cure Strategies. Ethical and social considerations. Short video on patients perspectives on cure
Outline Is HIV cure possible? Ø HIV persistence Cure Strategies Ethical and social considerations Short video on patients perspectives on cure A Case of Cure Off ART Treatment Mechanism Lesson The Berlin
More informationNo Conflict of Interest
No Conflict of Interest Aging and HIV Co-Morbidities: A Challenge for Engagement in Care Maria L Alcaide M.D. Division of Infectious Diseases University of Miami Miller School of Medicine Objectives Understand
More informationPART VI! IMPLICATIONS FOR THERAPIES
PART VI! IMPLICATIONS FOR THERAPIES Background Current HIV and aging treatment advice: Start ART early and manage traditional risk factors for non-aids-related diseases aggressively Treatments to reverse
More informationImpact of ART in Primary HIV infection on T cell immune exhaustion in Gut- associated lymphoid tissue: Implications for HIV persistence
Impact of ART in Primary HIV infection on T cell immune exhaustion in Gut- associated lymphoid tissue: Implications for HIV persistence THORNHILL J, MARTIN GE, HERRERA C, HOPKINS E, FIDLER S, FRATER J
More informationThe Impact of Immunoglobulin in Acute HIV Infection on the HIV Reservoir: A Pilot Randomized Controlled Trial
The Impact of Immunoglobulin in Acute HIV Infection on the HIV Reservoir: A Pilot Randomized Controlled Trial Olubanke Davies Guy s & St Thomas NHS Foundation Trust BACKGROUND Immediate ART during acute
More informationThe future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD
The future of HSCT John Barrett, MD, NHBLI, NIH Bethesda MD Transplants today Current approaches to improve SCT outcome Optimize stem cell dose and source BMT? PBSCT? Adjusting post transplant I/S to minimize
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationImpact of antiretroviral therapy on gut immunology and the HIV reservoir in elite controllers
Impact of antiretroviral therapy on gut immunology and the HIV reservoir in elite controllers Connie J Kim (Abstract #185) Session: Building Better Therapeutics November 19, 2013 10:00am HIV Elite Controllers
More informationAcute Graft-versus-Host Disease (agvhd) Udomsak Bunworasate Chulalongkorn University
Acute Graft-versus-Host Disease (agvhd) Udomsak Bunworasate Chulalongkorn University Graft-versus-Host Disease (GVHD) Background GVHD is an immunologic reaction of the donor immune cells (Graft) against
More informationAgeing with HIV. Amsterdam Institute for Global Health and Development. University of Amsterdam The Netherlands
Ageing with HIV Peter Reiss Professor of Medicine Dept of Infectious Diseases, Tropical Medicine and Aids and Dept of Global Health Academic Medical Center Amsterdam Institute for Global Health and Development
More informationAdvances in HIV science and treatment. Report on the global AIDS epidemic,
HIV biomolecular advances and treatment updates David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia UNAIDS: global l HIV infections
More informationHIV / AIDS Pathogenesis 2 (treated infection)
HIV / AIDS Pathogenesis 2 (treated infection) Henning Drechsler, MD VA North Texas Health Care System UT Southwestern Medical Center Objectives Characterize HIV-1 (classification, structure and life cycle)
More informationHerpes virus co-factors in HIV infection
Herpes virus co-factors in HIV infection Dr Jane Deayton Barts and the London Queen Mary School of Medicine Introduction Herpes viruses very common and often coexist with HIV Establish life-long latent
More informationCombined IL-21 and IFNα treatment limits inflammation and delay viral rebound in ART-treated, SIV-infected macaques
Combined and IFNα treatment limits inflammation and delay viral rebound in ART-treated, SIV-infected macaques Mirko Paiardini Associate Professor, Emory University School of Medicine Yerkes National Primate
More informationPreventive and therapeutic HIV vaccines. Markus Bickel Infektiologikum Frankfurt
Preventive and therapeutic HIV vaccines Markus Bickel Infektiologikum Frankfurt No conflicts to declare Disclosures Background FAQ: by patients and colleagues Publication about promising results, especially
More informationBody & Soul. Research update, 25 October 2016
Body & Soul Research update, 25 October 2016 Updates from BHIVA conference on... Cure breakthrough or not? Long acting retrovirals what do they offer? When to start treatment asap post diagnosis? Media
More informationJournal of Infectious Diseases Advance Access published July 11, Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers
Journal of Infectious Diseases Advance Access published July 11, 2013 1 Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers Tae-Wook Chun 1,6, J. Shawn Justement 1, Danielle Murray
More informationInnovative diagnostics for HIV, HBV and HCV
Innovative diagnostics for HIV, HBV and HCV Dan Otelea National Institute for Infectious Diseases Bucharest, Romania Disclaimer No conflicts of interest Innovative diagnostics for HIV, HBV and HCV - is
More informationProfessor Anna Maria Geretti
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor Anna Maria Geretti Institute of Infection & Global Health, University of Liverpool 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT
More informationClinical Aspect and Application of Laboratory Test in Herpes Virus Infection. Masoud Mardani M.D,FIDSA
Clinical Aspect and Application of Laboratory Test in Herpes Virus Infection Masoud Mardani M.D,FIDSA Shahidhid Bh BeheshtiMdi Medical lui Universityit Cytomegalovirus (CMV), Epstein Barr Virus(EBV), Herpes
More informationSupplementary Figure 1. Gating strategy and quantification of integrated HIV DNA in sorted CD4 + T-cell subsets.
Supplementary information HIV reservoir size and persistence are driven by T-cell survival and homeostatic proliferation. Chomont, N., M. El Far, P. Ancuta, L. Trautmann, F. A. Procopio, B. Yassine-Diab,
More information2/10/2015. Switching from old regimens. HIV treatment revision: As simple as old versus new? What is an old regimen? What is an old regimen?
Switching from old regimens David Nolan Department of Immunology, Royal Perth Hospital, Western Australia Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia What is
More informationInves)gación básica y curación del VIH- 1
Inves)gación básica y curación del VIH- 1 Javier Mar)nez- Picado (jmpicado@irsicaixa.es) 23 rd Conference on Retroviruses and Opportunis5c Infec5ons February 22-25, 2016 Boston, Massachuse8s UNIVERSITAT
More informationDifferential responses of human colonic ILCs to gut commensal bacteria altered during HIV infection
Differential responses of human colonic ILCs to gut commensal bacteria altered during HIV infection Moriah J. Castleman, Ph.D. Laboratory of Dr. Cara Wilson University of Colorado Anschutz Medical Campus
More informationEradication of HIV infection Not in my lifetime? or Just around the Corner? Michael M. Lederman, MD
Eradication of HIV infection Not in my lifetime? or Just around the Corner? Michael M. Lederman, MD Conflicts of Interest The pending clinical trials discussed here are funded by grant awards from Gilead
More informationHIV Eradication and the Quest for Functional Cure
HIV Eradication and the Quest for Functional Cure Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures Consultant and/or research support
More informationThe Struggle with Infectious Disease. Lecture 6
The Struggle with Infectious Disease Lecture 6 HIV/AIDS It is generally believed that: Human Immunodeficiency Virus --------- causes ------------- Acquired Immunodeficiency Syndrome History of HIV HIV
More informationAntigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS
1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family
More informationApproaching a Cure Daniel R. Kuritzkes, MD
Approaching a Cure Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker is a consultant and/or has received speaking honoraria
More informationOverview of the immune system
Overview of the immune system Immune system Innate (nonspecific) 1 st line of defense Adaptive (specific) 2 nd line of defense Cellular components Humoral components Cellular components Humoral components
More informationHIV Cure Update. Christine Durand, MD 14 de abril de 2016, XIII Conferência Brasil Johns Hopkins University em HIV/AIDS
HIV Cure Update Christine Durand, MD 14 de abril de 2016, XIII Conferência Brasil Johns Hopkins University em HIV/AIDS Financial Disclosures Research grants paid to my institution: Gilead Sciences, Bristol
More informationAddressing key gaps in cure research through identification and treatment of hyperacute HIV infection in a resource-limited setting
Addressing key gaps in cure research through identification and treatment of hyperacute HIV infection in a resource-limited setting Thumbi Ndung u, BVM, PhD KwaZulu-Natal Research Institute for Tuberculosis
More informationImmunity and Infection. Chapter 17
Immunity and Infection Chapter 17 The Chain of Infection Transmitted through a chain of infection (six links) Pathogen: Disease causing microorganism Reservoir: Natural environment of the pathogen Portal
More informationPediatric HIV Cure Research
Pediatric HIV Cure Research HIV Cure Research Training Curriculum Pediatric HIV Cure Research Presented by: Priyanka Uprety,MSPH, PhD Laboratory of Deborah Persaud, MD Johns Hopkins University July 2016
More information5. Over the last ten years, the proportion of HIV-infected persons who are women has: a. Increased b. Decreased c. Remained about the same 1
Epidemiology 227 April 24, 2009 MID-TERM EXAMINATION Select the best answer for the multiple choice questions. There are 60 questions and 9 pages on the examination. Each question will count one point.
More informationEffector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells
ICI Basic Immunology course Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells Abul K. Abbas, MD UCSF Stages in the development of T cell responses: induction
More informationInvited Review CROI 2018: Advances in Basic Science Understanding of HIV
Invited Review CROI 2018: Advances in Basic Science Understanding of HIV Mario Stevenson, PhD The conference on Retroviruses and Opportunistic Infections represents the most important venue for the dissemination
More informationDeterminants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco
Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?
More informationRationale for therapy at PHI
Rationale for therapy at PHI Immunological: Interfere with pathogenesis Preserve HIV-specific CD4+ T-help Reduce T-cell activation Virological: Prevent or reduce seeding of reservoirs Affect viral set
More informationState of the ART: HIV Cure where are we now and. where are we going? Jintanat Ananworanich, MD, PhD MHRP
State of the ART: HIV Cure where are we now and ì where are we going? Jintanat Ananworanich, MD, PhD Associate Director for Therapeu1cs Research US Military HIV Research Program (MHRP) Maryland, USA Deputy
More informationMortalité et Morbidité à l ère des traitements antirétroviraux dans les Pays du Nord
Mortalité et Morbidité à l ère des traitements antirétroviraux dans les Pays du Nord Laurence WEISS Hôpital Européen Georges Pompidou, Université Paris-Descartes Paris, France Deaths per 100 Person-Years
More information2 االستاذ المساعد الدكتور خالد ياسين الزاملي \ مناعة \ المرحلة الثانية \ التحليالت المرضية \
Innate Immunity Innate immunity: is the resistance that an individual possesses by birth. Innate immunity may be classified as (a) individual immunity (b) racial immunity (c) species immunity. Factors
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationOne Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases
One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital
More informationCuring HIV: Coping with Hope. Ronald Mitsuyasu, MD Professor of Medicine UCLA Center for Clinical AIDS Research and Education (CARE Center)
Curing HIV: Coping with Hope Ronald Mitsuyasu, MD Professor of Medicine UCLA Center for Clinical AIDS Research and Education (CARE Center) Curing HIV is: 0% A.Impossible 0% 0% 0% 0% 0% B. Requires removing
More informationPharmacology Considerations for HIV Prevention
Pharmacology Considerations for HIV Prevention Peter L. Anderson University of Colorado Anschutz Medical Campus Skaggs School of Pharmacy and Pharmaceutical Sciences Perspectives for next generation studies
More informationHIV/AIDS & Immune Evasion Strategies. The Year First Encounter: Dr. Michael Gottleib. Micro 320: Infectious Disease & Defense
Micro 320: Infectious Disease & Defense HIV/AIDS & Immune Evasion Strategies Wilmore Webley Dept. of Microbiology The Year 1981 Reported by MS Gottlieb, MD, HM Schanker, MD, PT Fan, MD, A Saxon, MD, JD
More informationPROSPECTS FOR HIV CURE IN ADULTS. Nov 11 th 2013 John Frater
PROSPECTS FOR HIV CURE IN ADULTS FIS 2013 Nov 11 th 2013 John Frater April 29 th 2013; Telegraph online THE COMPONENTS OF A CURE. What is cure? Issues to consider: Post treatment control the benefit of
More informationClinical Education Initiative CD4 CD8 CELL RATIOS IN INDIVIDUALS WITH ACUTE AND EARLY HIV INFECTION. Martin Hoenigl, MD
Clinical Education Initiative Support@ceitraining.org CD4 CD8 CELL RATIOS IN INDIVIDUALS WITH ACUTE AND EARLY HIV INFECTION Martin Hoenigl, MD 2/3/2017 CD4 CD8 Cell Ratios in Individuals with Acute and
More informationHIV-DNA: nuovo marcatore virologico. Metodiche a confronto per la quantificazione di HIV-DNA
HIV-DNA: nuovo marcatore virologico Metodiche a confronto per la quantificazione di HIV-DNA Maria Carla Re Laboratorio Retrovirus e Agenti infettivi HIV correlati UO di Microbiologia, Università di Bologna
More informationStatin Use and Cardiovascular Disease in HIV
Statin Use and Cardiovascular Disease in HIV Steven K. Grinspoon, MD Professor of Medicine Harvard Medical School Boston, Massachusetts FLOWED: 04/18/16 Los Angeles, California: April 25, 2016 Statin Use
More informationCTLA-4-expressing CD4 T cells are critical contributors to SIV viral persistence
IAS 2015 Towards an HIV Cure symposium Vancouver CTLA-4-expressing CD4 T cells are critical contributors to SIV viral persistence Colleen McGary Paiardini lab Emory University HIV reservoir prevents eradication
More informationPRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients
PRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients Jay Lalezari, Kush Dhody, Ula Kowalczyk, Kazem Kazempour, Nader Pourhassan, and Paul J. Maddon 1 ASM Microbe 2016
More information